(Press-News.org) In a new study, researchers from Intermountain Health in Salt Lake City have shown that by using a computerized clinical decision support tool to guide diagnosis and treatment in emergency department patients with pneumonia, they were able to reduce mortality rates, especially in patients experiencing socioeconomic hardships.
Pneumonia, a serious infection in the lungs that causes inflammation and difficulty breathing, is one of the most common causes of death worldwide. An estimated 150,000 people are hospitalized annually for pneumococcal pneumonia, and about 1 in 20 dies as a result.
While anyone can get pneumonia, some people are at risk, including young children, older adults, and people with certain chronic health conditions.
Pneumonia has also been found to disproportionately affect individuals and communities experiencing economic hardship. This is due to a combination of factors that increase susceptibility to the disease and reduce access to treatment and prevention.
ePneumonia was created in 2011 to predict and guide diagnosis and treatment of patients with pneumonia and is integrated into Intermountain’s Health normal workflow. It uses prior medical history, emergency department vital signs, findings on chest imaging lab results, and chest imaging findings.
“By using ePneumonia to predict who will be affected by pneumonia, we flattened the differences in mortality in patients across all social groups,” said Jason R. Carr, MD, an investigator in the study and pulmonary medicine specialist and researcher at Intermountain Health. “With this technology, we’re saving more lives, no matter where you come from.”
The Intermountain Health study findings were presented at the ATS 2025, the American Thoracic Society’s annual conference, which is being held this year in San Francisco.
The study examined whether use of ePneumonia improved outcomes in patients with higher Area Deprivation Indexes (ADI), a calculation that scores socioeconomic disadvantage based on poverty, education, housing and employment. The higher the score, the more socially disadvantaged the individual.
Patients with high ADI are of particular concern in Utah, which has rural areas with areas that may experience economic challenges.
In the study, Intermountain researchers looked at the clinical impact that implementation of ePneumonia had on patients at 16 Intermountain Health community hospitals across Utah from June 2016 to June 2019.
They did so by identifying adults with emergency department and hospital discharge diagnosis codes from pneumonia or sepsis/respiratory failure associated with pneumonia that was confirmed by X-rays by emergency departments.
Researchers found that overall, ePneumonia was associated with significant reduction in mortality among patients with pneumonia who also had high ADI scores, meaning that fewer people at higher risk died of pneumonia.
The team believes that ePneumonia reduces unconscious bias in physicians’ calculations on who has pneumonia, and treatment decisions, said Nathan C. Dean, MD, a study investigator and at Intermountain Medical Center in Murray.
Artificial intelligence is built into ePneumonia and it reduces inappropriate deviation from best practices of care, said Dr. Dean.
“Physicians may not realize they’re doing this, but it happens. These findings show that having help from a tool like ePneumonia helps our patients by helping physicians overcome those unconscious biases they might not see themselves to ensure all patients are getting the best care possible,” he added.
These preliminary results are encouraging but need further study for confirmation, said Dr. Carr.
###
END
Study finds pneumonia computerized clinical decision support reduces mortality disparities in patients facing economic hardships
2025-05-21
ELSE PRESS RELEASES FROM THIS DATE:
Mount Sinai researchers uncover a promising new way to modulate brain cell activity to potentially treat major depressive disorder in adults
2025-05-21
A mechanism involving potassium channels in the brain that control brain cell activity could provide a new and fundamentally different way of treating depression symptoms in adults with major depressive disorder, according to two complementary papers published recently by researchers at the Icahn School of Medicine at Mount Sinai.
In two new research articles, published in Biological Psychiatry and Molecular Psychiatry, the researchers provide new insights into how a drug called ezogabine may impact the brain to improve depression.
“Depression is a devastating ...
New clues to autism: epigenetic study identifies RABGGTB as a novel candidate gene
2025-05-21
Autism spectrum disorder (ASD) is a condition affecting the brain’s development and often affects the ability of a person to perceive sensory information and social cues and socialize with others. Recent studies have revealed that environmental factors and epigenetic processes, such as DNA methylation, are crucial to the development of ASD. Notably, immune activation and exposure to stress hormones are known to alter neuronal activity in the dorsal raphe (DR, a region of the brain involved in serotonin signaling), contributing ...
EuroPCR 2025 – Meta-analysis of individual patient data from the PROTECTED TAVR and BHF PROTECT-TAVI trials
2025-05-21
Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among which is the meta-analysis of data from the PROTECTED TAVR and BHF PROTECT TAVI Trials
Background
The embolisation of debris after transaortic valve implantation (TAVI) for the treatment of aortic stenosis can lead to stroke. Cerebral embolic protection (CEP) devices, which can capture this debris and thus lower the incidence of stroke, have been deployed during ...
EuroPCR 2025 – The FAITAVI trial: angiography versus physiology-guided PCI in patients undergoing TAVI – 12-month follow-up data
2025-05-21
Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among them is the FAITAVI randomised clinical trial (RCT).
Background
The optimal management of patients with intermediate coronary artery disease (CAD) and severe aortic stenosis (AS) who are candidates for TAVI remains unclear. Recent trials comparing percutaneous coronary intervention ...
EuroPCR 2025 – One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
2025-05-21
Background
While dual antiplatelet therapy (DAPT) has long been the standard of care for the management of acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI), there is an increasing awareness of the need to find a more patient-centred approach that strikes a balance between the ischaemic protection DAPT offers and the risk of bleeding complications it can create.
The effect of DAPT in dosage and duration on cardiovascular events and bleeding after implantation of drug-coated stents (DCS) in ACS patients, ...
PREVENT equation accurately estimated 10-year CVD risk and those with calcium buildup
2025-05-21
Research Highlights:
The American Heart Association’s PREVENTTM risk calculator accurately identified participants who had calcium buildup in their heart arteries and those who had a higher future heart attack risk, in an analysis of about 7,000 adults in New York City referred for heart disease screening.
The PREVENT scores also predicted future heart attack risk.
Embargoed until 4 a.m. CT/5 a.m. ET Wednesday, May 21, 2025
DALLAS, May 21, 2025 — The PREVENTTM risk calculator helped to identify people with plaque buildup in the arteries of the heart, in addition to predicting their risk of a future heart attack, according ...
Nano-engineered thermoelectrics enable scalable, compressor-free cooling
2025-05-21
Researchers at the Johns Hopkins Applied Physics Laboratory (APL) in Laurel, Maryland, have developed a new, easily manufacturable solid-state thermoelectric refrigeration technology with nano-engineered materials that is twice as efficient as devices made with commercially available bulk thermoelectric materials. As global demand grows for more energy-efficient, reliable and compact cooling solutions, this advancement offers a scalable alternative to traditional compressor-based refrigeration.
In a paper published in ...
Researchers identify a dual origin of cells controlling puberty and reproduction
2025-05-21
Researchers at the Francis Crick Institute have shown that gonadotrophs, cells in the pituitary gland with a key role in puberty and reproduction, come from two different populations, with the majority produced after birth rather than in the embryo, as previously thought.
A better understanding of when these important cells develop could help researchers and clinicians understand and treat disorders that impact puberty and fertility.
In the pituitary, a small gland located in the middle of the head and connected to the brain, gonadotrophs ...
Major step for flat and adjustable optics
2025-05-21
By carefully placing nanostructures on a flat surface, researchers at Linköping University, Sweden, have significantly improved the performance of so-called optical metasurfaces in conductive plastics. This is a major step for controllable flat optics, with future applications such as video holograms, invisibility materials, and sensors, as well as in biomedical imaging. The study has been published in the journal Nature Communications.
To control light, curved lenses are used today, that are often made of glass that is either concave or convex, ...
Less frequent stroke monitoring is safe, effective, and frees up resources, study finds
2025-05-21
Halving the number of times vital signs and neurological function are checked in low-risk patients after treatment for acute ischaemic stroke does not compromise care or recovery, according to new findings presented at the 11th European Stroke Organisation Conference in Helsinki, Finland.
Results from the Optimal Post rTpa-Iv Monitoring in Ischaemic Stroke Trial (OPTIMISTmain)1, simultaneously published in The Lancet, also showed that this approach also had flow-on benefits for nursing workflow and intensive care resources. The trial was led by Professor Craig Anderson from The George Institute for Global Health and UNSW ...